Healthcare Industry News: drug-eluting stent
News Release - May 13, 2008
ENDEAVOR II Four-Year Results Demonstrate Long-Term Safety and Durable Efficacy of Medtronic Drug-Eluting StentUpdate at EuroPCR Shows Sustained Superiority of Endeavor(R) DES over Bare-Metal Control
MINNEAPOLIS & BARCELONA, Spain--(HSMN NewsFeed)--Today at EuroPCR, Medtronic, Inc. (NYSE: MDT ), released four-year data from the ENDEAVOR II clinical trial that reinforces the long-term safety and durable efficacy of the company’s Endeavor Zotarolimus-Eluting Coronary Stent System for the treatment of coronary artery disease.
“As the duration of follow-up in ENDEAVOR II grows, so too does our confidence in the enduring safety and effectiveness of the Endeavor stent,” said Dr. Jean Fajadet of the Clinique Pasteur Unité de Cardiologie Interventionnelle in Tolouse, France, who presented the data at the late-breaking clinical trials session. “The durability of this device’s performance is remarkable based on these four-year results, which show low rates of late adverse events.”
The newly released data indicate that the Endeavor stent offers durable efficacy out to four years of follow-up, with no new events requiring target lesion revascularization (TLR) between years three and four. They also reinforce the long-term safety record of the Endeavor stent, which was associated with no new episodes of stent thrombosis over the same period.
Compared with Medtronic’s Driver bare-metal stent (the control in ENDEAVOR II), these trial results show a lower rate of target vessel failure (TVF) for patients treated with the Endeavor stent – due largely to a diminished rate of target vessel revascularization (TVR). TVF is a composite of TVR, myocardial infarction and cardiac death.
Through four years of clinical follow-up with more than 97 percent of patients in each arm of ENDEAVOR II, the rate of:
- TLR was 7.2 percent for the Endeavor group compared to 15.8 percent for the Driver group, representing a 54 percent reduction (p<0.001) in the need for repeat procedures
- TVR was 9.8 percent for Endeavor patients and 18.8 percent for Driver patients, a 48 percent reduction (p<0.001)
- TVF, the trial’s primary endpoint (assessed at nine months), was 13.6 percent for Endeavor and 22.6 percent for Driver, a 40 percent reduction (p<0.001)
- Major Adverse Cardiac Events (MACE) was 13.4 percent for Endeavor and 22.1 percent for Driver, a 39 percent reduction (p<0.001)
In addition, rates of cardiac death, myocardial infarction (MI) and the combination of the two were numerically fewer (although not to a statistically significant degree) in the Endeavor group through four years of follow-up:
- Cardiac death – Endeavor 2.4% (14/581); Driver 2.6% (15/584)
- MI – Endeavor 3.3% (19/581); Driver 4.5% (26/584)
- Cardiac death plus MI – Endeavor 5.3% (31/581); Driver 7.0% (41/584)
Part of the comprehensive ENDEAVOR clinical program, ENDEAVOR II is a double-blind randomized controlled trial designed to compare the Endeavor drug-eluting stent with the Driver bare-metal on safety and efficacy metrics. The international trial enrolled 1,197 patients from 72 medical centers in Europe, Asia Pacific, Israel, Australia and New Zealand. With one-to-one randomization, half of the patients received the Endeavor stent (n = 598); the other half, the Driver stent (n = 599). Published in the August 2006 issue of Circulation, ENDEAVOR II demonstrated the superiority of the Endeavor stent on the primary endpoint of TVF at nine months: Endeavor 7.9%; Driver 15.1% – a 48% reduction (p<0.001). The Endeavor stent was also superior to the Driver stent on the secondary endpoint of TLR at nine months: Endeavor 4.6%; Driver 11.8% – a 61% reduction (p<0.001).
Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology – alleviating pain, restoring health, and extending life for millions of people around the world.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic’s Annual Report on Form 10-K for the year ended April 27, 2007. Actual results may differ materially from anticipated results.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsAustin L. Chiang, M.D., M.P.H. Joins Medtronic As Chief Medical Officer for Gastrointestinal Business
Medtronic Hugo(TM) Robotic-Assisted Surgery System Receives European CE Mark Approval
Medtronic Expands Minimally Invasive Spine Surgery Ecosystem with Next-Generation Spinal Technologies